Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. - Wikidata - awgldk - TriplyDB

Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis.

Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis.

http://www.wikidata.org/entity/Q33835268

about

The microglial "activation" continuum: from innate to adaptive responses Translational utility of experimental autoimmune encephalomyelitis: recent developments CD40-CD40 Ligand Interactions Promote Trafficking of CD8+ T Cells into the Brain and Protection against West Nile Virus Encephalitis Inhibition of CD40-TRAF6 interactions by the small molecule inhibitor 6877002 reduces neuroinflammation.Modulation of the CD40-CD40 ligand interaction using human anti-CD40 single-chain antibody fragments obtained from the n-CoDeR phage display library.Identification of three novel peptides that inhibit CD40-CD154 interaction.Role of CD40-CVD40L in mouse severe malaria.Determination of Genes Related to Uveitis by Utilization of the Random Walk with Restart Algorithm on a Protein-Protein Interaction Network.Characterization of the CD154-positive and CD40-positive cellular subsets required for pathogenesis in retrovirus-induced murine immunodeficiency.Endogenous presentation of self myelin epitopes by CNS-resident APCs in Theiler's virus-infected mice The CD40/CD40 ligand interaction is required for resistance to toxoplasmic encephalitis.Mycobacterium bovis BCG-induced granuloma formation depends on gamma interferon and CD40 ligand but does not require CD28.A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice.Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis.CD154 blockade results in transient reduction in Theiler's murine encephalomyelitis virus-induced demyelinating disease.Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.Targeting T cell costimulation in autoimmune disease.Increased CD40+ Fibrocytes in Patients With Idiopathic Orbital Inflammation.Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.T cell costimulatory pathways: blockade for autoimmunity.Activation of microglia by borna disease virus infection: in vitro study The critical role of antigen-presentation-induced cytokine crosstalk in the central nervous system in multiple sclerosis and experimental autoimmune encephalomyelitis.Emerging disease modifying therapies for multiple sclerosis.CD40-CD40L interactions induce chemokine expression by human microglia: implications for human immunodeficiency virus encephalitis and multiple sclerosis.CD40-CD40 ligand disruption does not prevent hyperoxia-induced injury Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.Chemokines Referee Inflammation within the Central Nervous System during Infection and Disease Th40 cells (CD4+CD40+ Tcells) drive a more severe form of Experimental Autoimmune Encephalomyelitis than conventional CD4 T cells.Controlled release strategies for modulating immune responses to promote tissue regeneration The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system.Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases.Molecular targets for disrupting leukocyte trafficking during multiple sclerosis.Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.Modulating co-stimulation.PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE.CD40 and autoimmunity: the dark side of a great activator.CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease?T-cell response dynamics in animal models of multiple sclerosis: implications for immunotherapies.Novel therapeutic strategies targeting the pathogenic T-cells in multiple sclerosis.Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.

P2860

Q24814335-A2BF2DFC-92AE-44D0-8AD1-613CEEB3D70A Q26775820-B9CE9106-10E5-4EDD-ADEC-EFA2E63234BC Q27481468-026D28CC-A364-4BD4-AE98-A5DEC9442DAF Q30849102-5D9A3A03-5185-43D7-8BD5-05AA1CE3B378 Q31100421-843B5949-8E14-44A5-86D5-0986C182C287 Q33259767-DF0702ED-FB43-400E-ABA1-D6AE3B8157E1 Q33338408-34415B44-3632-4181-9596-C0BF7370EF43 Q33755275-0E386E8A-7846-42B1-A790-FC3172D6FB73 Q33851104-D30A838C-720E-4FD5-8F21-30990F0C6D90 Q33858153-640EB62E-A876-4BF0-8967-6909EB9F3B6A Q34003535-F299F7D6-1A57-4632-A97F-1158086E6C3F Q34006992-FB578EC0-6BAA-435F-849B-D518896299F2 Q34283011-91C03B26-A1BF-454F-B93F-79DBA1109444 Q34307160-DA539905-0DFB-4653-877C-80E4E47A4666 Q34466815-FBE156D2-7E30-4DB3-B508-AF5A742520C8 Q34787127-B818B246-1CDD-42A2-93E7-E0EFDC716872 Q34837371-9C1CE0BC-60D4-47D7-A4B2-CC10C7286146 Q35054706-244DD1D3-A148-42B6-848E-70BFF59CCA76 Q35088106-3803E7E7-9BB7-494E-96C9-061922627CCF Q35093604-502B88EC-93A4-4722-8C15-3FF36D51B2F6 Q35185949-FD06B6F3-BEA5-444D-8FF8-B6E3DA6239E7 Q35294476-CE23249A-5218-49C1-998D-2AE61A838278 Q35581158-4A73E17C-C8A9-45AA-A43F-C62A92E520F6 Q35747327-9ED995A1-98AD-429A-A38F-6C56CA55EE01 Q35788667-408BC266-3EB7-4D56-9EA6-9030C5C83090 Q35994774-580959A4-E322-4154-A7D2-DDEBD2036F76 Q36112729-71FF2AAC-8242-4263-83B1-9831468EF192 Q36278572-ADDF4300-123B-4489-A499-BBA185B3981F Q36307642-0DEB4378-8B53-4AB5-AB9B-2C1F6CE6FE94 Q36369234-AC98F280-A63E-469F-B10C-7DF388F230FC Q36810295-A09487EF-002C-492A-9541-F0E464EAEEBE Q36885184-C9929D22-74EC-4C7D-8810-6B99A9CE0FEB Q36919720-7B037416-866D-4770-A1AD-05D99589EB16 Q36963201-03D0EF2D-E429-4967-9A00-AB2E266BB0F8 Q37307349-1B28DCD9-41CF-49A8-AA61-A9228D4FBA8D Q37365433-B456B567-6E8B-4DC7-AA53-11E69FDD8F86 Q37411386-4540FE38-27C7-4F33-8DB8-012E228183EF Q37754572-92751257-A28D-4519-A2DA-FF154845A4A8 Q37754616-8ED09BF5-8890-49E8-BF3C-57DABF9DEB04 Q38286209-FD45A2E0-A619-447A-B2FE-CC728EF57397

P2860

Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis.

http://www.wikidata.org/entity/Q33835268

description

1999 nî lūn-bûn

@nan

1999 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի հունվարին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@ast

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@en

type

label

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@ast

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@en

prefLabel

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@ast

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@en

P1433

Q33835268-45BFC81E-AE51-4C3D-ADB2-B2BB147AE2D9

P1476

Q33835268-7198FA66-E8CC-42C4-A511-B21FB7F6359B

P2093

Q33835268-019BB1B4-1611-40A6-9ACD-EA71FE4C632E

Q33835268-0CCD69AD-95BA-4131-889F-A7513AB9673D

Q33835268-12CB03FE-E1D0-47E9-9C6B-C2AE45F3B3CA

Q33835268-2F5F3C70-7835-43AD-B0AA-93B1C69ADEA7

Q33835268-C04B053B-E230-44F5-93F8-27E8ACED31EC

Q33835268-E1DE0293-2341-40D2-A0F4-7562C84CBE4E

Q33835268-F99C7557-4446-4B43-B399-F5F79FFF01FE

P2860

Q33835268-017ED852-F036-4FBE-B08E-C314EFC9D1FB

Q33835268-02DB8BEF-65E7-48FA-8C73-1972A22CFEAE

Q33835268-036BF003-9AEA-47A1-B29A-2E63886F0790

Q33835268-07BC0464-A136-4869-BA43-62A57CBA279B

Q33835268-0900AC2B-D061-492D-8B78-12E7B1EBC75C

Q33835268-0F4F8C12-3D35-453E-AAA9-794896F78FBF

Q33835268-1215F5A3-D782-4883-9A19-8B4D8E5CECCB

Q33835268-294C0612-BD44-4910-A666-7F003F1BE1BA

Q33835268-382EBBA7-9378-4E9B-8504-300718C1E990

Q33835268-38341604-BCAA-4671-B324-8AE4E3F9DDE4

P304

Q33835268-8A21A37F-D2B6-4A88-AC1D-46022F8D7556

P31

Q33835268-B6C8F99B-7D7E-4D57-99F6-A636F4E38AD7

P356

Q33835268-1BF52D2D-F660-44F0-BB86-9EFF3527E316

P407

Q33835268-77A2A9D9-B8AA-43D1-9A05-C141844609C2

P433

Q33835268-6D8A98F6-3A2F-4390-9ABE-7D317D4B78E5

P478

Q33835268-261F6AA8-474F-41C9-BE1A-75F5E354AB00

P577

Q33835268-586574F5-3568-48F4-94A4-157EF73920A0

P698

Q33835268-CC748F1B-BB02-4E71-BFE4-A1CEFBD0F5D7

P921

Q33835268-B6C09197-F30E-4D6B-A023-93ED4B96FACE

Q33835268-B701A7E6-0B55-4961-8AC8-2777E0B5A6C8

Q33835268-C143307F-F29F-4B25-99E2-7F34568569BE

P932

Q33835268-417BA7F3-C737-4882-A661-516160CFE5FD

P356

P1433

Journal of Clinical Investigation

P1476

Mechanisms of immunotherapeuti ...... l model of multiple sclerosis.

@en

P2093

A J Miga

http://www.w3.org/2001/XMLSchema#string

C L Vanderlugt

http://www.w3.org/2001/XMLSchema#string

J D Laman

http://www.w3.org/2001/XMLSchema#string

L M Howard

http://www.w3.org/2001/XMLSchema#string

M C Dal Canto

http://www.w3.org/2001/XMLSchema#string

R J Noelle

http://www.w3.org/2001/XMLSchema#string

S D Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation

The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells.

Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand.

Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection.

Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease.

Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis

Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion.

CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy.

P304

281-290

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI5388

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

1999-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

9916140

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

P932

407886

http://www.w3.org/2001/XMLSchema#string